The bi-specific CD3 x NCAM antibody: a model to preactivate T cells prior to tumour cell lysis.
Kemshead, John T
Von Bergwelt-Baildon, M S
Schultze, J L
AffiliationDepartment of Pediatric Oncology and Hematology, University of Cologne, Germany. email@example.com
MetadataShow full item record
AbstractTo target the neural cell adhesion molecule (NCAM, CD56) on neuroblastoma by T cell-based immunotherapy we have generated a bi-specific CD3 x NCAM antibody (OE-1). This antibody can be used to redirect T cells to NCAM+ cells. Expectedly, the antibody binds specifically to NCAM+ neuroblastoma cells and CD3+ T cells. OE-1 induces T cell activation, expansion and effector function in peripheral blood mononuclear cell (PBMC)-derived CD4+ and CD8+ T cells. T cell activation was shown to depend on the presence of normal natural killer (NK) cells in the culture. Interestingly, while PBMC- derived T cells were activated by OE-1, NK cells were almost completely depleted, suggesting that T cells activated by OE-1 deleted the NK cells. Activated CD4+ and CD8+ T cells differentiate into a larger CCR7+ central memory and a smaller CCR7- effector memory cell population. Most importantly, preactivated T cells were highly cytotoxic for neuroblastoma cells. In eight of 11 experiments tumour-directed cytotoxicity was enhanced when NK cells were present during preactivation with OE-1. These data strongly support a bi-phasic therapeutic concept of primarily stimulating T cells with the bi-specific antibody in the presence of normal NCAM+ cells to induce T cell activation, migratory capacity and finally tumour cell lysis.
CitationThe bi-specific CD3 x NCAM antibody: a model to preactivate T cells prior to tumour cell lysis. 2003, 134 (2):253-63 Clin. Exp. Immunol.
JournalClinical and Experimental Immunology